Stockscreener 앱 받기
0.39
1.30%
0.005
시간 외 거래:
.37
-0.02
-5.13%
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
Mersana Therapeutics to Present at Upcoming Investor Conferences | MRSN Stock News - GuruFocus
Mersana Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
William Blair Analysts Lift Earnings Estimates for MRSN - Defense World
Q2 EPS Estimate for Mersana Therapeutics Lifted by Analyst - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $3.67 Average Price Target from Analysts - Defense World
Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00 - Defense World
Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer - MSN
Mersana Therapeutics (NASDAQ:MRSN) Earns Outperform Rating from Wedbush - Defense World
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates - MSN
MRSN: Truist Securities Raises Price Target for Mersana Therapeutics | MRSN Stock News - GuruFocus
MRSN: Guggenheim Reiterates Buy Rating with $5 Price Target | MRSN Stock News - GuruFocus
Mersana Therapeutics (MRSN) Target Price Increased by Truist | MRSN Stock News - GuruFocus
Mersana Therapeutics price target raised to $10 from $9 at Truist - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating - marketscreener.com
Truist raises Mersana stock target to $10, maintains Buy rating By Investing.com - Investing.com Nigeria
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Earnings call transcript: Mersana Therapeutics reports Q1 2025 loss, stock up 6.14% - Investing.com Nigeria
Truist raises Mersana stock target to $10, maintains Buy rating - Investing.com
Mersana Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CORRECTIONMersana Therapeutics Provides Business Update and A - GuruFocus
Mersana Therapeutics, Inc. SEC 10-Q Report - TradingView
Mersana Cancer Drug Shows Strong 31% Response Rate in Latest Trial Data, Reports Q1 Financial Results - Stock Titan
Mersana Therapeutics (MRSN) Reports Lower Q1 Revenue and Shares - GuruFocus
Mersana Therapeutics Provides Business Update and Announces Firs - GuruFocus
Mersana Therapeutics Q1 2025 Financial Results and Business Update - TradingView
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results - GlobeNewswire
Clinical Trial Results: Mersana's New Cancer Drug Achieves 31% Response Rate in Hard-to-Treat Tumors - Stock Titan
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Barclays PLC Sells 311,805 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Wedbush Expects Stronger Earnings for Mersana Therapeutics - Defense World
Petri Dish: Cancer biotech cuts staff; Lantheus sells business unit - The Business Journals
Bluebird pleads for deal support; Unity, Mersana lay off staff - BioPharma Dive
Wedbush Cuts Price Target on Mersana Therapeutics to $3 From $4, Maintains Outperform Rating - marketscreener.com
Mersana Therapeutics announces restructuring plans; shares fall - TradingView
Mersana Therapeutics Announces Restructuring and Reprioritization Plan - citybiz
Mersana Therapeutics (MRSN) Announces Major Restructuring Strate - GuruFocus
Mersana Therapeutics Announces Strategic Restructuring and Repri - GuruFocus
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer | MRSN Stock News - GuruFocus
Mersana Therapeutics announces strategic cutbacks amid economic pressures - Investing.com
Mersana Therapeutics Announces Strategic Restructuring to Extend Cash Runway and Focus on Emi-Le Development - Nasdaq
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer - GlobeNewswire
Mersana Slashes Workforce by 55%, Doubles Down on Promising Breast Cancer Drug Pipeline - Stock Titan
MRSN stock touches 52-week low at $0.56 amid market challenges - MSN
Mersana Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Mersana Therapeutics Inc [MRSN] stock for 2,061 USD was sold by Mandelia Ashish - knoxdaily.com
Renaissance Technologies LLC Has $867,000 Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics Inc (MRSN) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Mersana Therapeutics (MRSN) Expected to Announce Earnings on Thursday - Defense World
XTX Topco Ltd Sells 283,725 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
MRSN (Mersana Therapeutics Inc) may reap gains as insiders became active recently - knoxdaily.com
Holdings of Mersana Therapeutics Inc (MRSN) are aligned with the stars - Sete News
Investors’ Faith in Mersana Therapeutics Inc (MRSN) could reap rewards if they hold on for the long haul - uspostnews.com
2.33%
1.09%
자본화:
|
볼륨(24시간):